Jacob P Laubach

32PUBLICATIONS
123CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Oct 05, 2026
Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial.

|Jun 10, 2025
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment.

Nicolas A Gort-Freitas, Maria Moscvin, Matteo C Da Vià

|Jun 05, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Andrew R Branagan, Clifton Mo, Matthew Lei

|Dec 03, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Andrew J Yee, Jacob P Laubach, Erica L Campagnaro

|Aug 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns

|Jul 26, 2024
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.

Peter Voorhees, Vera Suman, Yvonne Efebera

Pageof 6

Frequent Collaborators

22 joint publications

Paul Richardson

6 joint publications

Andrew J Yee

5 joint publications

Andrew R Branagan

4 joint publications

Larry D Anderson